Amp Fund Performance since Jan 2017

About AMP 

At Amp, we research biopharma companies primarily with valuations between $200M and $5B, who have upcoming catalyst events in the next 12 months, and invest in some of these companies in the Amp Hedge Fund, LP, as well as a series of hypothetical funds where we test different strategies. The performance above is based on our hypothetical Amp 1.0 fund from January 1, 2017 to July 1, 2018, and since then based on our real hedge fund (Amp Fund, LP). 

To learn more about Amp, see the About Amp page.


Amp Biopharma Investment Blog

Our free blog features periodic and shortened company and investment updates.  Amp Core members get all updates and our full quarterly and company reports. Learn More


To view only our blog posts for biopharma investors that are a collaboration between Amp and our Double Helix Law IP team, CLICK HERE

November 15, 2019

Today, an advisory committee appointed by the FDA met and voted to recommend to the FDA that it expands the label for AMRN's cardiovascular drug Vascepa based on the landmark, large multi-year Reduce-It trial results, initially reported last year and published in the N...

July 2, 2019

Central nervous system (CNS) disorder drug development is a particularly difficult branch of biopharma drug development. ITCI has experienced this first hand, with inconsistent late stage results for ITI-007 (Lumateperone), a promising therapy for certain CNS disorders...

June 26, 2019

GLYC has what is likely to be a binary event reading out later this year, likely in the next 45 days, with the phase 3 readout of its partnered-out drug rivipansel for the treatment of vaso-occlusive crises (VOCs) in patients with sickle cell disease (SCD). We find it...

Please reload


Contact Us

Interested and want to learn more? Send us a note below. 

*Disclaimer: Information provided on and in any of our reports, products and services, including our Amp Core™ product, are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action. 

By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here.

Amp Core™ is a trademark of Amp Biotech Research, LLC

©2019 BY Amp Biotech Research